Therapy Areas: Diabetes
Destiny Pharma selects MedPharm as expert partner to produce topical formulations of XF-platform compounds
28 March 2019 -

Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, has chosen MedPharm as its expert partner to develop new topical formulations of the Company's novel XF-platform compounds, it is reported today.

The new topical formulations are part of the company's second clinical programme to address the global problem of anti-microbial resistance

The XF platform has already delivered a Phase two ready candidate, XF-73 nasal gel, for the prevention of post-surgical infections, that is to commence in Phase 2b testing in 2019. MedPharm will develop new formulations containing Destiny Pharma's XF-platform compounds for the treatment of various topically treated infections, including diabetic foot ulcers and ophthalmic infections.

Login
Username:

Password: